Skip to main content

Table 1 Baseline characteristics of study participants included in the analysis

From: Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

 

Study 1 INVOLVE [16]

Study 2 INHANCE [17]

Study 3 INLIGHT 1 [18]

Total

n

1377

1575

361

3313

Age, years

64 (8)

64 (9)

63 (10)

64 (9)

Male/female, %

78/22

63/37

52/48

69/31

Body mass index, kg/m2

27 (5)

27 (6)

28 (7)

27 (6)

FEV1, % predicted*

53 (14)

56 (14)

55 (14)

55 (14)

FEV1/FVC, %*

51 (10)

53 (10)

53 (10)

52 (10)

Pre-bronchodilator FEV1, l

1.35 (0.43)

1.33 (0.49)

1.34 (0.51)

1.34 (0.47)

Post-bronchodilator FEV1, l*

1.52 (0.47)

1.50 (0.50)

1.51 (0.52)

1.51 (0.49)

Reversibility, %*

13.2 (13.4)

15.5 (15.9)

16.0 (18.7)

14.6 (15.3)

ICS use yes/no, %

55/45

38/62

32/68

45/55

Smoker/ex-smoker, %

40/60

44/56

52/48

43/57

BDI score

6.6 (2.2)

6.5 (2.3)

NA

6.5 (2.2)

SGRQ total score

44 (18)

45 (18)

49 (19)

45 (18)

Treatments

    

   Placebo, n

322

311

176

809

   Indacaterol 75 μg, n

0

67

0

67

   Indacaterol 150 μg, n

0

346

185

531

   Indacaterol 300 μg, n

363

357

0

720

   Indacaterol 600 μg, n

344

68

0

412

   Formoterol 12 μg, n

348

75

0

423

   Tiotropium 18 μg, n

0

351

0

351

  1. Data are mean (standard deviation) unless otherwise stated. *Measured 30 min after salbutamol 400 μg inhalation. Reversibility was calculated as the difference between the pre- and post-bronchodilator values of FEV1 (in l) as a percentage of the pre-bronchodilator value; BDI, Baseline Dyspnoea Index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; INVOLVE, INdacaterol: Value in COPD: Longer term Validation of Efficacy and safety; INHANCE, INdacaterol versus tiotropium to Help Achieve New COPD treatment Excellence; INLIGHT, INdacaterol: efficacy evaLuation usInG 150 μg doses with COPD PatienTs; NA, not available; SGRQ, St George's Respiratory Questionnaire.